Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.

Trial Profile

Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEW CHOICE
  • Sponsors Agile Therapeutics
  • Most Recent Events

    • 27 Jul 2017 According to an Agile Therapeutics media release, the US FDA has accepted for review the Company's NDA resubmission for Twirla (AG200-15). The NDA resubmission was submitted on June 26, 2017. The FDA stated that it considers the resubmission to be a complete response to the CRL and established December 26, 2017 as the Prescription Drug User Fee Act (PDUFA) goal date.
    • 01 Jun 2013 Results were presented at the American College of Obstetricians and Gynecologists' (ACOG) 61st Annual Clinical Meeting, according to an Agile Therapeutics media release.
    • 08 May 2013 Tolerability results presented at the 61st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top